Related Experiment Video
Updated: Jun 11, 2026

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
Published on: February 5, 2019
Assessment of Enteral Baclofen Prescribing Practices for Infants With Hypertonia
Hope E DiTaranto1, Astrela Moore1, Rebecca Kendsersky1
1Department of Pharmacy (HED, AM, RK, JZ), Children's Hospital of Philadelphia, Philadelphia, PA.
Insights
This study analyzed enteral baclofen use in infants under 12 months for hypertonia. Prescribing varied, but baclofen was generally safe and well-tolerated, offering insights for infant dosing.
Area of Science:
- Pediatric Neurology
- Pharmacology
- Clinical Pharmacy
Background:
- Hypertonia in infants often requires management with medications like baclofen.
- Existing dosing guidance for infant baclofen is limited, leading to practice variability.
Purpose of the Study:
- To describe the enteral baclofen prescribing patterns in infants 12 months of age and younger.
- To assess the safety and tolerability of baclofen regimens in this population.
Main Methods:
- A single-center, retrospective review of infants receiving enteral baclofen from January 2013 to December 2022.
- Analysis of regimen details: dose, frequency, age, weight, and treatment duration.
- Evaluation of outcomes including place in therapy, safety, and tolerability.
Main Results:
- 108 infants with 423 baclofen regimens were analyzed.
- Initiation doses were generally lower than recommended, with a median weight-based total daily dose (wTDD) of 0.5 mg/kg/day.
- The longest-tolerated regimen had a median wTDD of 1.3 mg/kg/day; adverse effects were infrequent (3.7%).
Conclusions:
- Infant baclofen prescribing for hypertonia shows significant variability in practice.
- The analyzed baclofen regimens were found to be safe and well-tolerated in infants.
- Findings offer valuable insights into current baclofen dosing strategies for pediatric hypertonia.
Objective:
Baclofen is used for hypertonia in infants despite limited dosing guidance. This study describes enteral baclofen prescribing in patients 12 months of age and younger.
Methods:
This single-center, retrospective review evaluated infants receiving enteral baclofen from January 2013 to December 2022. Regimen information, including dose, frequency, age, weight, and duration of treatment for up to 1 year following initiation, was assessed. Other outcomes included place in therapy, safety, and tolerability.
Results:
This study included 108 patients with 423 total regimens. At initiation, the median baclofen dose was 1.3 mg, corresponding to a weight-based dose (WBD) of 0.2 mg/kg, a total daily dose (TDD) of 3 mg, and a weight-based total daily dose (wTDD) of 0.5 mg/kg/day. Sixty-one patients (56.5%) received baclofen 3 times daily at initiation. The patients' longest-tolerated regimen had a median dose of 2.8 mg, corresponding to a WBD of 0.4 mg/kg, a TDD of 9 mg, and a wTDD of 1.3 mg/kg/day. Hypoxemic-ischemic encephalopathy and brain injury were the most common etiologies of hypertonia. Baclofen was the first antispastic agent for 37 patients (34.3%). Twenty-four patients (22.2%) discontinued baclofen within 1 year. Four patients (3.7%) stopped baclofen due to adverse effects (sedation and emesis).
Conclusions:
The median initiation dose of baclofen in infants was lower than the recommended dose for patients aged younger than 2 years, highlighting variability in practice. The baclofen regimens used in this study were safe and well-tolerated. These findings provide insight into baclofen prescribing for infants with hypertonia.
Related Concept Videos
Drug Dosing: Infants and Children
Skeletal Muscle Relaxants: Therapeutic Uses
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Alterations in Muscle Tone ll
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
